Roots of new biotech startup begin with Yale discovery and a $10 billion deal

test test
Craig Crews, left, in his laboratory.

More than a decade ago, Yale scientist Craig Crews’ curiosity about why a natural product had anti-cancer properties led to the development of a drug to combat multiple myeloma, which California pharmaceutical company Amgen recently paid $10.4 billion to acquire.

Now Crews, the Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology, and professor of chemistry and of pharmacology, has launched Arvinas, a new biotechnology company in New Haven developing a novel way to treat cancers.

On Sept. 26, the company announced it had raised $15 million in equity financing and $3.25 million in loan financing from the state of Connecticut. For more on the new startup and its history, click here.

Share this with Facebook Share this with Twitter Share this with LinkedIn Share this with Email Print this

Media Contact

Bill Hathaway: william.hathaway@yale.edu, 203-432-1322